Plasma Protease C1 Inhibitor Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028
| Published: Jan 2024 | Pages: 166 | SKU: IRTNTR72978 |
Plasma Protease C1 Inhibitor Market 2024-2028
The global plasma protease C1 inhibitor market size is estimated to grow by USD 2.00 billion, at a CAGR of 7.55% between 2023 and 2028.
The plasma protease C1 inhibitor market is anticipated to grow owing to biopharmaceutical firms' increased attention on developing effective plasma protease C1 inhibitor treatment drugs/therapy for various health conditions like HAE, diabetic macular edema (DME), and others. Several kallikrein inhibitor medicines are now in the preclinical and clinical stages of development. For instance, in March 2022, KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced the initiation of the KVD900 Phase 3 KONFIDENT Clinical Trial evaluating efficacy and safety as the first potential oral, on-demand therapy for HAE attacks. Thus, such an increase in R&D related to plasma protease C1 inhibitors is expected to drive market growth during the forecast period.
Technavio has segmented the market into End-user, Product, and Geography
- The end-user segment includes hospital pharmacy, retail pharmacy, and online pharmacy
- The product segment includes lyophilized and injectable
- The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)
It also includes an in-depth analysis of drivers, trends, and challenges. Our market research and growth report examines historical data from 2018-2022, besides analyzing the current market scenario.
What will be the size of the Plasma Protease C1 Inhibitor Market During the Forecast Period?
To learn more about this report, Download Report Sample
Segmentation by End-user, Product, and Geography Analysis
End-user Analysis
Hospital Pharmacy
The market share growth by the hospital pharmacy segment will be significant during the forecast period. Hospital pharmacies are responsible for procuring, storing, and dispensing this critical medication to patients. One of the key factors driving the growth of the hospital pharmacy segment in the global plasma protease C1 inhibitor market is the rising prevalence of hereditary angioedema worldwide. In addition, hospital pharmacies play a crucial role in ensuring the accessibility and availability of plasma protease C1 inhibitors for HAE patients.
Get a glance at the market contribution of various segments Download PDF Sample
The hospital pharmacy segment was valued at USD 1.78 billion in 2018. Furthermore, close collaboration between hospital pharmacies and other healthcare providers helps in improving treatment outcomes and patient satisfaction. Thus, by ensuring availability, offering comprehensive pharmaceutical care, and collaborating with healthcare professionals, hospital pharmacies contribute significantly to the successful management of HAE and enhancing patient outcomes, which in turn will drive the growth of the hospital pharmacy segment in the market during the forecast period.
Product Analysis
Lyophilized
Lyophilization, also known as freeze-drying, is a process that involves removing water from a product while keeping its structure intact. In the context of plasma protease C1 inhibitors, lyophilized forms are utilized to enhance their stability, prolong shelf life, and facilitate ease of storage and transportation. Lyophilized plasma protease C1 inhibitors find extensive application in the treatment of HAE, a rare genetic disorder characterized by recurrent episodes of swelling in various body parts such as the skin, gastrointestinal tract, and respiratory system. Further, the development of lyophilized formulations underscores the commitment of pharmaceutical companies and researchers to address unmet medical needs and improve the lives of patients with rare genetic disorders. Hence, the increased benefits of lyophilized will drive the growth of the lyophilized segment in the market during the forecast period.
Injectable
The global plasma protease C1 inhibitor market is witnessing substantial growth, and one of the notable segments within it is the injectable segment. Injectable plasma protease C1 inhibitor products are administered directly into the bloodstream to treat various medical conditions, particularly HAE. These injectable therapies are designed to restore or supplement the deficient or malfunctioning C1 inhibitor protein in individuals suffering from this rare genetic disorder. The injectable segment of the global plasma protease C1 inhibitor market focuses on ensuring rapid and effective delivery of C1 inhibitor proteins to address acute HAE attacks. Thus, such innovations aim to enhance convenience, optimize dosage, and improve patient comfort during the forecast period.
Regional Analysis
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Due to increased HAE and increasing R&D investments, North America dominates the plasma protease C1 inhibitor market. The presence of well-established healthcare infrastructure and prominent market participants providing effective treatment options to patients suffering from HAE in North America are important growth drivers.
Additionally, many organizations are spreading awareness about the treatment of HAE, like the US Hereditary Angioedema Association, a non-profit organization dedicated to offering HAE patients access to the latest treatment options and dependable, personal support to address symptoms and the challenges associated with the condition. Hence, such factors are expected to drive market growth in this region during the forecast period.
Key Market Players
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AstraZeneca Plc: The company offers plasma protease C1 inhibitor through its subsidiary Alexion Pharmaceuticals such as Soliris which is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
- Bausch Health Companies Inc.
- Bio Techne Corp.
- BioCryst Pharmaceuticals Inc.
- Biosynth Ltd.
- Bristol Myers Squibb Co.
- Cayman Chemical
- CSL Ltd.
- FibroGen Inc.
- Fresenius SE and Co. KGaA
- Gilead Sciences Inc.
- Ionis Pharmaceuticals Inc.
- KalVista Pharmaceuticals Inc.
- Merck KGaA
- Novartis AG
- Pharming Group NV
- Sino Biological Inc.
- Takeda Pharmaceutical Co. Ltd.
- Thermo Fisher Scientific Inc.
- Vertex Pharmaceuticals Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Key Drivers, Trends, Challenges, and Customer Landscape
There are multiple factors influencing market growth analysis. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Key Drivers
Increasing product approvals/launches of plasma protease C1 inhibitors is the key factor driving market growth. As new treatments and therapies are developed offer better options for patients suffering from hereditary angioedema (HAE) and other related disorders. This has led to increased competition among pharmaceutical companies to bring their products to market, resulting in a surge of approvals and launches. For instance, Takeda Pharmaceutical Co. Ltd. presented seven abstracts regarding its therapeutic options for HAE at the 2023 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Antonio, Texas, on February 24-27.
Therefore, the market witnessed a surge in product approvals and launches as companies sought to capture a share of the growing demand for C1 inhibitor treatments. This trend of increasing product approvals and launches has ensured a continuous stream of novel therapies entering the market. Additionally, the broader availability of these treatments has led to heightened awareness about HAE and increased diagnosis rates, which will further drive the growth of the market during the forecast period.
Significant Trends
Growing adoption of bradykinin B2 receptor antagonists is the primary trend shaping market growth. Plasma protease C1 inhibitors act as a regulatory factor in inhibiting the activation of the complement and contact systems, including the production of bradykinin. However, in certain disorders such as hereditary angioedema (HAE), the levels of plasma protease C1 inhibitors are insufficient, resulting in uncontrolled bradykinin release. To address this issue, Bradykinin B2 receptor antagonists have emerged as a promising therapeutic approach aligned with market trends and analysis.
Additionally, advancements in drug development and increasing research activities in the field of bradykinin-related disorders have expanded the range of available options for the treatment of disorders such as HAE. Pharmaceutical companies are investing in the development of novel Bradykinin B2 receptor antagonists to offer improved efficacy, convenience, and patient compliance. In addition, the rising prevalence of HAE and other related disorders across the world will further fuel the growth of the market during the forecast period.
Major Challenges
High cost and complex treatment of plasma protease C1 inhibitor is a challenge that affects market growth. If proper guidelines are not followed during the preparation of therapeutics as well as during consumption, plasma protease C1 inhibitor treatment can become very complicated. Current treatments have some drawbacks, such as infection risk, treatment resistance, low compliance, and side effects. Plasma-based medicines are linked to an increased risk of blood-borne diseases such as human immunodeficiency virus (HIV), hepatitis B, and hepatitis C transmission.
However, even though primary blood screening is performed, the risk of infection transmission during transfusion remains significant. This is due to the occurrence of various pathogen strains, blood purification-resistant pathogens, and the threat of new viruses such as flaviviruses. This leads to the development of negative immunological reactions to blood-based products, resulting in treatment non-compliance. Thus, such factors are expected to impede market growth during the forecast period.
Key Market Customer Landscape
The market analysis and report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
Segment Overview
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends opportunities from 2018 to 2028.
- End-user Outlook
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
- Product Outlook
- Lyophilized
- Injectable
- Region Outlook
- North America
- The U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Rest of Europe
- Asia
- China
- India
- Rest of World (ROW)
- Argentina
- Australia
- Brazil
- North America
|
Plasma Protease C1 Inhibitor Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
166 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.55% |
|
Market Growth 2024-2028 |
USD 2.00 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
7.12 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bio Techne Corp., BioCryst Pharmaceuticals Inc., Biosynth Ltd., Bristol Myers Squibb Co., Cayman Chemical, CSL Ltd., FibroGen Inc., Fresenius SE and Co. KGaA, Gilead Sciences Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Merck KGaA, Novartis AG, Pharming Group NV, Sino Biological Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download the Sample PDF at your Fingertips
What are the Key Data Covered in this Market Research Report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the market forecast between 2024 and 2028
- Precise estimation of the size and its contribution to the market in focus on the parent market
- Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
- Companies landscape comparing criticality of inputs and factors of differentiation
- Exclusive Matrix on companies' position and classification
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the growth of companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2023
- 3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
- 4.1 Global plasma protease C1 inhibitor market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global plasma protease c1 inhibitor market 2018 - 2022 ($ billion)
- 4.2 End-user Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – End-user Segment 2018 - 2022 ($ billion)
- 4.3 Product Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
- 4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
- 4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by End-user
- 6.1 Market segments
- Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
- Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
- 6.2 Comparison by End-user
- Exhibit 32: Chart on Comparison by End-user
- Exhibit 33: Data Table on Comparison by End-user
- 6.3 Hospital pharmacy - Market size and forecast 2023-2028
- Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
- 6.4 Retail pharmacy - Market size and forecast 2023-2028
- Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
- 6.5 Online pharmacy - Market size and forecast 2023-2028
- Exhibit 42: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ billion)
- Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
- 6.6 Market opportunity by End-user
- Exhibit 46: Market opportunity by End-user ($ billion)
- Exhibit 47: Data Table on Market opportunity by End-user ($ billion)
7 Market Segmentation by Product
- 7.1 Market segments
- Exhibit 48: Chart on Product - Market share 2023-2028 (%)
- Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
- 7.2 Comparison by Product
- Exhibit 50: Chart on Comparison by Product
- Exhibit 51: Data Table on Comparison by Product
- 7.3 Lyophilized - Market size and forecast 2023-2028
- Exhibit 52: Chart on Lyophilized - Market size and forecast 2023-2028 ($ billion)
- Exhibit 53: Data Table on Lyophilized - Market size and forecast 2023-2028 ($ billion)
- Exhibit 54: Chart on Lyophilized - Year-over-year growth 2023-2028 (%)
- Exhibit 55: Data Table on Lyophilized - Year-over-year growth 2023-2028 (%)
- 7.4 Injectable - Market size and forecast 2023-2028
- Exhibit 56: Chart on Injectable - Market size and forecast 2023-2028 ($ billion)
- Exhibit 57: Data Table on Injectable - Market size and forecast 2023-2028 ($ billion)
- Exhibit 58: Chart on Injectable - Year-over-year growth 2023-2028 (%)
- Exhibit 59: Data Table on Injectable - Year-over-year growth 2023-2028 (%)
- 7.5 Market opportunity by Product
- Exhibit 60: Market opportunity by Product ($ billion)
- Exhibit 61: Data Table on Market opportunity by Product ($ billion)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 63: Chart on Market share by geography 2023-2028 (%)
- Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
- 9.2 Geographic comparison
- Exhibit 65: Chart on Geographic comparison
- Exhibit 66: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2023-2028
- Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
- 9.4 Europe - Market size and forecast 2023-2028
- Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
- 9.5 Asia - Market size and forecast 2023-2028
- Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- 9.7 US - Market size and forecast 2023-2028
- Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
- 9.8 Germany - Market size and forecast 2023-2028
- Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
- 9.9 UK - Market size and forecast 2023-2028
- Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
- 9.10 China - Market size and forecast 2023-2028
- Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
- 9.11 Japan - Market size and forecast 2023-2028
- Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
- 9.12 Market opportunity by geography
- Exhibit 103: Market opportunity by geography ($ billion)
- Exhibit 104: Data Tables on Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 105: Impact of drivers and challenges in 2023 and 2028
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 107: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 108: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 109: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 110: Matrix on vendor position and classification
- 12.3 AstraZeneca Plc
- Exhibit 111: AstraZeneca Plc - Overview
- Exhibit 112: AstraZeneca Plc - Product / Service
- Exhibit 113: AstraZeneca Plc - Key news
- Exhibit 114: AstraZeneca Plc - Key offerings
- 12.4 Bausch Health Companies Inc.
- Exhibit 115: Bausch Health Companies Inc. - Overview
- Exhibit 116: Bausch Health Companies Inc. - Business segments
- Exhibit 117: Bausch Health Companies Inc. - Key news
- Exhibit 118: Bausch Health Companies Inc. - Key offerings
- Exhibit 119: Bausch Health Companies Inc. - Segment focus
- 12.5 Bio Techne Corp.
- Exhibit 120: Bio Techne Corp. - Overview
- Exhibit 121: Bio Techne Corp. - Business segments
- Exhibit 122: Bio Techne Corp. - Key offerings
- Exhibit 123: Bio Techne Corp. - Segment focus
- 12.6 BioCryst Pharmaceuticals Inc.
- Exhibit 124: BioCryst Pharmaceuticals Inc. - Overview
- Exhibit 125: BioCryst Pharmaceuticals Inc. - Product / Service
- Exhibit 126: BioCryst Pharmaceuticals Inc. - Key offerings
- 12.7 Biosynth Ltd.
- Exhibit 127: Biosynth Ltd. - Overview
- Exhibit 128: Biosynth Ltd. - Product / Service
- Exhibit 129: Biosynth Ltd. - Key offerings
- 12.8 Bristol Myers Squibb Co.
- Exhibit 130: Bristol Myers Squibb Co. - Overview
- Exhibit 131: Bristol Myers Squibb Co. - Product / Service
- Exhibit 132: Bristol Myers Squibb Co. - Key news
- Exhibit 133: Bristol Myers Squibb Co. - Key offerings
- 12.9 Cayman Chemical
- Exhibit 134: Cayman Chemical - Overview
- Exhibit 135: Cayman Chemical - Product / Service
- Exhibit 136: Cayman Chemical - Key offerings
- 12.10 CSL Ltd.
- Exhibit 137: CSL Ltd. - Overview
- Exhibit 138: CSL Ltd. - Business segments
- Exhibit 139: CSL Ltd. - Key offerings
- Exhibit 140: CSL Ltd. - Segment focus
- 12.11 Fresenius SE and Co. KGaA
- Exhibit 141: Fresenius SE and Co. KGaA - Overview
- Exhibit 142: Fresenius SE and Co. KGaA - Business segments
- Exhibit 143: Fresenius SE and Co. KGaA - Key news
- Exhibit 144: Fresenius SE and Co. KGaA - Key offerings
- Exhibit 145: Fresenius SE and Co. KGaA - Segment focus
- 12.12 Ionis Pharmaceuticals Inc.
- Exhibit 146: Ionis Pharmaceuticals Inc. - Overview
- Exhibit 147: Ionis Pharmaceuticals Inc. - Business segments
- Exhibit 148: Ionis Pharmaceuticals Inc. - Key news
- Exhibit 149: Ionis Pharmaceuticals Inc. - Key offerings
- Exhibit 150: Ionis Pharmaceuticals Inc. - Segment focus
- 12.13 KalVista Pharmaceuticals Inc.
- Exhibit 151: KalVista Pharmaceuticals Inc. - Overview
- Exhibit 152: KalVista Pharmaceuticals Inc. - Product / Service
- Exhibit 153: KalVista Pharmaceuticals Inc. - Key offerings
- 12.14 Sino Biological Inc.
- Exhibit 154: Sino Biological Inc. - Overview
- Exhibit 155: Sino Biological Inc. - Product / Service
- Exhibit 156: Sino Biological Inc. - Key offerings
- 12.15 Takeda Pharmaceutical Co. Ltd.
- Exhibit 157: Takeda Pharmaceutical Co. Ltd. - Overview
- Exhibit 158: Takeda Pharmaceutical Co. Ltd. - Product / Service
- Exhibit 159: Takeda Pharmaceutical Co. Ltd. - Key news
- Exhibit 160: Takeda Pharmaceutical Co. Ltd. - Key offerings
- 12.16 Thermo Fisher Scientific Inc.
- Exhibit 161: Thermo Fisher Scientific Inc. - Overview
- Exhibit 162: Thermo Fisher Scientific Inc. - Business segments
- Exhibit 163: Thermo Fisher Scientific Inc. - Key news
- Exhibit 164: Thermo Fisher Scientific Inc. - Key offerings
- Exhibit 165: Thermo Fisher Scientific Inc. - Segment focus
- 12.17 Vertex Pharmaceuticals Inc.
- Exhibit 166: Vertex Pharmaceuticals Inc. - Overview
- Exhibit 167: Vertex Pharmaceuticals Inc. - Product / Service
- Exhibit 168: Vertex Pharmaceuticals Inc. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 169: Inclusions checklist
- Exhibit 170: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 171: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 172: Research methodology
- Exhibit 173: Validation techniques employed for market sizing
- Exhibit 174: Information sources
- 13.5 List of abbreviations
- Exhibit 175: List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
PURCHASE FULL REPORT OF
plasma protease c1 inhibitor market market
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
- Off-the-shelf research reports
- Reports can be tailored to meet the customer's needs
- Trusted by more than 100 fortune 500 organizations
- Information about the market's key drivers, trends, and challenges
- Parent market analysis
- Every week, 50,000 people visit our subscription platform
- Detailed vendors report with competitive landscape
- Covid-19 impact and recovery analysis
- Data on revenue-generating market segments
- Details on the market shares of various regions
- Five-force market analysis